A
Alain Bouckenooghe
Researcher at Sanofi Pasteur
Publications - 83
Citations - 8065
Alain Bouckenooghe is an academic researcher from Sanofi Pasteur. The author has contributed to research in topics: Dengue vaccine & Dengue fever. The author has an hindex of 29, co-authored 83 publications receiving 7378 citations. Previous affiliations of Alain Bouckenooghe include Sanofi S.A. & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more
TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Journal ArticleDOI
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
Hadinegoro,José Luis Arredondo-García,Maria Rosario Capeding,Carmen Deseda,Chotpitayasunondh T,Reynaldo Dietze,Muhammad Ismail Hi,Humberto Reynales,Kriengsak Limkittikul,Doris Maribel Rivera-Medina,Tran Hn,Alain Bouckenooghe,Danaya Chansinghakul,Margarita Cortés,Fanouillere K,Forrat R,Carina Frago,Sophia Gailhardou,Jackson N,Fernando Noriega,Eric Plennevaux,Tram Anh Wartel,Betzana Zambrano,Melanie Saville +23 more
TL;DR: Although the unexplained higher incidence of hospitalization for dengue in year 3 among children younger than 9 years of age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 years ofAge was lower in the vaccine group than in the control group.
Journal ArticleDOI
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding,Ngoc Huu Tran,Sri Rezeki Hadinegoro,Hussain Imam Muhammad Ismail,Tawee Chotpitayasunondh,Mary Noreen Chua,Chan Quang Luong,Kusnandi Rusmil,Dewa Nyoman Wirawan,Revathy Nallusamy,Punnee Pitisuttithum,Usa Thisyakorn,In-Kyu Yoon,Diane van der Vliet,Edith Langevin,Thelma Laot,Yanee Hutagalung,Carina Frago,Mark Boaz,T. Anh Wartel,Nadia Tornieporth,Melanie Saville,Alain Bouckenooghe +22 more
TL;DR: The findings show that dengue vaccine is efficacious when given as three injections at months 0, 6, and 12 to children aged 2-14 years in endemic areas in Asia, and has a good safety profile.
Journal ArticleDOI
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon,Derek Wallace,Chukiat Sirivichayakul,Kriengsak Limkittikul,Pornthep Chanthavanich,Saravudh Suvannadabba,Vithaya Jiwariyavej,Wut Dulyachai,Krisana Pengsaa,T. Anh Wartel,Annick Moureau,Melanie Saville,Alain Bouckenooghe,Simonetta Viviani,Nadia Tornieporth,Jean Lang +15 more
TL;DR: These data show for the first time that a safe vaccine against dengue is possible, and Dengue vaccine was well tolerated, with no safety signals after 2 years of follow-up after the first dose.
Journal ArticleDOI
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study
Timo Vesikari,Aino Karvonen,Roman Prymula,Volker Schuster,J. C. Tejedor,Robert Cohen,F Meurice,H.H. Han,Silvia Damaso,Alain Bouckenooghe +9 more
TL;DR: In a European setting, two doses of RIX4414 coadministered with childhood vaccines provided high protection against any and severe rotavirus gastroenteritis, with an overall reduction of admissions for gastroEnteritis over two consecutive rotav virus epidemic seasons.